Spectrum Solutions v. Longhorn Vaccines: Cross-Appeals Dismissed at Federal Circuit
Spectrum Solutions LLC filed and then voluntarily withdrew cross-appeals against Longhorn Vaccines & Diagnostics LLC at the Federal Circuit, ending a multi-docket challenge over US9683256B2 — a patent covering biological specimen collection and transport systems. The dismissal, unopposed and covering five consolidated appeal numbers, resolved in 180 days.
Federal Circuit cross-appeal withdrawn before merits review
Case No. 24-2365 is one of five consolidated cross-appeal dockets (2024-2361 through 2024-2365) filed at the United States Court of Appeals for the Federal Circuit on September 26, 2024. The appellant, Spectrum Solutions LLC, asserted rights relating to US9683256B2 — a patent directed to biological specimen collection and transport systems — against Longhorn Vaccines & Diagnostics LLC in an invalidity/cancellation dispute rooted in patentability.
On March 25, 2025, Spectrum Solutions filed an unopposed motion to dismiss all five cross-appeal numbers and to withdraw from the remaining appeals. The Federal Circuit granted the motion, terminating the proceedings without any ruling on the merits. Because the dismissal was unopposed and the record does not specify whether it was with or without prejudice, the precise preclusive effect on future proceedings remains publicly unclear.
The 180-day lifecycle from filing to closure is notably short for Federal Circuit patent invalidity appeals, suggesting the parties likely reached some form of accommodation — or Spectrum strategically abandoned the appellate track — before briefing reached completion. The public record is silent on any underlying settlement or licensing terms, and no cost award is recorded.
Filing to Appeal Dismissed in 180 days
180-day appeal lifecycle — faster than the Federal Circuit median for patent invalidity appeals
Cross-appeals voluntarily withdrawn: what the dismissal means for both parties
Unopposed motion to dismiss: procedure without merits
Spectrum Solutions invoked a voluntary dismissal of its own cross-appeals across five consolidated Federal Circuit docket numbers. An unopposed motion signals Longhorn did not contest the withdrawal — consistent with either a negotiated resolution or Spectrum electing not to pursue the appellate challenge. Critically, no court ruled on the validity or enforceability of US9683256B2, leaving the substantive patentability questions unresolved on the appellate record.
No merits ruling issuedSpectrum exits the Federal Circuit without a ruling
By moving to dismiss its own cross-appeals, Spectrum Solutions forfeits any appellate determination on the patentability issues it raised. The public record does not specify whether dismissal was with or without prejudice, which matters significantly: if with prejudice, Spectrum cannot re-raise those appellate arguments; if without prejudice, future proceedings remain possible. IP professionals should note this distinction is unresolved from public filings alone.
Prejudice status: publicly unclearLonghorn avoids Federal Circuit merits review — for now
Longhorn Vaccines & Diagnostics secured a termination of Spectrum’s cross-appeals without any appellate ruling affirming or reversing the lower tribunal’s patentability findings. This outcome removes near-term appellate risk from Spectrum’s challenge, though it does not necessarily resolve the broader dispute. Longhorn’s non-opposition to dismissal suggests it was either satisfied with the existing posture or party to an undisclosed arrangement.
No adverse ruling receivedUS9683256B2 enforceability remains in legal ambiguity
For companies operating in biological specimen collection, diagnostics, and nucleic acid preservation, the withdrawal of these cross-appeals without merits resolution means the patent’s validity has not been appellate-confirmed or cancelled. Competitors and licensees should treat US9683256B2 as a live enforcement risk until further proceedings, if any, clarify its scope and validity status. FTO analysis against this patent remains advisable for the sector.
Patent validity: unresolved by this appealFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Spectrum Solutions, LLC | Company | Biological specimen collection technology company — holder of US9683256B2Search in Eureka ↗ |
| Defendant | Longhorn Vaccines & Diagnostics, LLC | Company | Longhorn Vaccines & Diagnostics LLC — diagnostics and biological materials companySearch in Eureka ↗ |
| Plaintiff counsel | Benjamin Bruce Anger | Attorney | Counsel for Spectrum Solutions, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Morgan, Lewis & Bockius, LLP | Law Firm | Representing Spectrum Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Christie Corn | Attorney | Counsel for Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Defendant counsel | David M. Krinsky | Attorney | Counsel for Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Defendant counsel | John Marcus McNichols | Attorney | Counsel for Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Defendant law firm | Williams & Connolly LLP | Law Firm | Representing Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Presiding judge | Judge PROST | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s disposition reflects a purely procedural termination: Spectrum Solutions moved to dismiss its own cross-appeals and to withdraw from remaining proceedings, with Longhorn filing no opposition. No standard of review was applied and no substantive patentability determination was made. The operative effect is that the appellate dockets are closed, but the underlying merits — invalidity or validity of US9683256B2 — remain unresolved at the Federal Circuit level. Both parties’ positions on patentability are preserved for any future proceedings.
US9683256B2 — Biological specimen collection and transport system
US9683256B2, filed under application number US14/969339, protects a biological specimen collection and transport system — technology directed at preserving biological materials, most likely including nucleic acids such as DNA and RNA, from point of collection through laboratory analysis. This category of patent covers critical infrastructure for diagnostics workflows, including collection devices, stabilisation chemistries, and transport media. The patent’s commercial relevance was amplified significantly by demand for robust specimen collection systems during and after the COVID-19 pandemic.
For the diagnostics and molecular biology sector, US9683256B2 represents a potentially broad blocking position on specimen collection and transport workflows. Longhorn Vaccines & Diagnostics and Spectrum Solutions are both active in this space, making the enforceability of this patent strategically significant for product development, OEM supply chains, and laboratory service providers. The unresolved appellate status following the cross-appeal dismissal means competitors cannot rely on a Federal Circuit validity ruling and should conduct independent FTO analysis.
Should your team run an FTO against US9683256B2?
Any company developing, manufacturing, or distributing biological specimen collection devices, transport media, or nucleic acid stabilisation systems should assess exposure to US9683256B2. The patent’s validity was contested but not resolved by the Federal Circuit in this proceeding, meaning it remains a live assertion risk. R&D teams designing collection swabs, transport tubes, or preservation chemistries for diagnostic applications should treat this patent as in-force until further proceedings clarify its status.
PatSnap Eureka’s FTO Search Agent can map US9683256B2’s claim scope against your product pipeline, identify prior art cited in the PTAB and district court proceedings, and flag continuations or related applications that may extend the patent family’s reach. For diagnostics product teams entering the specimen collection market, a structured FTO review using Eureka reduces the risk of inadvertent infringement in a legally ambiguous post-dismissal environment.
Run a freedom-to-operate analysis on US9683256B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in biological specimen and diagnostics patents
Federal Circuit cases involving biological specimen collection, nucleic acid preservation, and diagnostics patentability — including voluntary dismissals and PTAB-appeal interactions.
What this case signals for the diagnostics and specimen collection IP landscape
A multi-docket Federal Circuit withdrawal resolved in 180 days — here is what it means for IP strategy in biological specimen collection.
Voluntary Federal Circuit dismissal leaves patent validity legally unresolved
When a cross-appellant voluntarily withdraws at the Federal Circuit before merits briefing concludes, no appellate precedent is set. For US9683256B2, this means patentability arguments raised by Spectrum were never adjudicated at the appellate level. Companies in the specimen collection and diagnostics space should not interpret the dismissal as confirmation of validity or invalidity.
Five consolidated dockets dismissed simultaneously — signals strategic coordination
The simultaneous dismissal of five cross-appeal numbers (2024-2361 through 2024-2365) is consistent with a coordinated resolution rather than unilateral abandonment. This pattern typically signals an underlying business arrangement — licensing, settlement, or cross-licensing — even where the public record is silent. Monitoring subsequent licensing activity or related PTAB proceedings involving these parties is advisable.
Spectrum v Longhorn — key questions answered
Spectrum Solutions LLC voluntarily moved to dismiss its cross-appeals (Nos. 2024-2361 through 2024-2365) at the Federal Circuit before any merits ruling was issued. The motion was unopposed by Longhorn Vaccines & Diagnostics LLC, and the court terminated the proceedings on March 25, 2025. No ruling on the validity or enforceability of US9683256B2 was made.
No. The Federal Circuit dismissed Spectrum Solutions’ cross-appeals without reaching the merits of the patentability dispute. The validity and enforceability of US9683256B2 was not adjudicated at the appellate level in this proceeding. Any findings from the lower tribunal proceedings remain operative but were not reviewed by the Federal Circuit.
An unopposed dismissal terminates the appellate proceeding without any merits ruling. The patent in dispute — here US9683256B2 — is neither confirmed as valid nor cancelled by the appellate court. The appellee’s non-opposition suggests either a negotiated resolution or acceptance of the existing procedural posture. The preclusive effect depends on whether dismissal was with or without prejudice, which the public record does not specify.
US9683256B2, filed as US application 14/969339, covers a biological specimen collection and transport system. This technology relates to devices and methods for collecting biological samples — such as swabs or collection tubes — and preserving them for transport to diagnostic laboratories, typically involving nucleic acid stabilisation chemistry relevant to DNA and RNA-based diagnostic workflows.
Potentially, depending on whether the dismissal was with or without prejudice — a distinction the public record does not clarify. If dismissed without prejudice, Spectrum retains optionality to pursue alternative enforcement routes, including new district court actions or PTAB proceedings. If with prejudice, the dismissed appellate arguments may be foreclosed. Parties monitoring this dispute should watch for subsequent PTAB petitions or district court filings involving these parties.
PatSnap Eureka searches patents and litigation data to answer instantly.